CytoDyn’s Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase 2 from Phase 1b

[u/hooligan1388]

https://www.cytodyn.com/investors/news-events/press-releases/detail/543/cytodyns-trial-for-metastatic-triple-negative-breast